SE512412C2 - Farmaceutisk komposition i kapselform bestående av ranitidin och en icke-vattenhaltig grundmassa - Google Patents

Farmaceutisk komposition i kapselform bestående av ranitidin och en icke-vattenhaltig grundmassa

Info

Publication number
SE512412C2
SE512412C2 SE9000625A SE9000625A SE512412C2 SE 512412 C2 SE512412 C2 SE 512412C2 SE 9000625 A SE9000625 A SE 9000625A SE 9000625 A SE9000625 A SE 9000625A SE 512412 C2 SE512412 C2 SE 512412C2
Authority
SE
Sweden
Prior art keywords
filling
ranitidine
mixture
composition according
weight
Prior art date
Application number
SE9000625A
Other languages
English (en)
Swedish (sv)
Other versions
SE9000625L (sv
SE9000625D0 (sv
Inventor
Sham Kumar Chopra
Tribhovan Tarun Makadia
Original Assignee
Glaxo Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Canada filed Critical Glaxo Canada
Publication of SE9000625D0 publication Critical patent/SE9000625D0/xx
Publication of SE9000625L publication Critical patent/SE9000625L/
Publication of SE512412C2 publication Critical patent/SE512412C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE9000625A 1989-02-23 1990-02-22 Farmaceutisk komposition i kapselform bestående av ranitidin och en icke-vattenhaltig grundmassa SE512412C2 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898904182A GB8904182D0 (en) 1989-02-23 1989-02-23 Pharmaceutical compositions

Publications (3)

Publication Number Publication Date
SE9000625D0 SE9000625D0 (sv) 1990-02-22
SE9000625L SE9000625L (sv) 1990-08-24
SE512412C2 true SE512412C2 (sv) 2000-03-13

Family

ID=10652220

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9000625A SE512412C2 (sv) 1989-02-23 1990-02-22 Farmaceutisk komposition i kapselform bestående av ranitidin och en icke-vattenhaltig grundmassa

Country Status (26)

Country Link
US (1) US5028432A (nl)
JP (1) JP2856817B2 (nl)
KR (1) KR940006271B1 (nl)
AT (1) AT401727B (nl)
AU (1) AU629303B2 (nl)
BE (1) BE1003123A3 (nl)
CA (1) CA2010692C (nl)
CH (1) CH680567A5 (nl)
CY (1) CY1734A (nl)
DE (1) DE4005650C2 (nl)
DK (1) DK170209B1 (nl)
FR (1) FR2643263B1 (nl)
GB (2) GB8904182D0 (nl)
HK (1) HK89493A (nl)
HU (1) HU211930A9 (nl)
IE (1) IE63179B1 (nl)
IL (1) IL93490A (nl)
IT (1) IT1240768B (nl)
LU (1) LU87681A1 (nl)
NL (1) NL193267C (nl)
NZ (1) NZ232642A (nl)
PH (1) PH26972A (nl)
SA (1) SA90100287B1 (nl)
SE (1) SE512412C2 (nl)
ZA (1) ZA901348B (nl)
ZW (1) ZW1790A1 (nl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0548238A1 (en) * 1990-09-13 1993-06-30 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
US5571533A (en) * 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
MX9306393A (es) * 1992-10-16 1994-04-29 Glaxo Group Ltd Composiciones de ranitidina substancialmente libres de sabor amargo, proceso para su preparacion y composiciones farmaceuticas que las contienen.
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
GB9705813D0 (en) * 1997-03-20 1997-05-07 Smithkline Beecham Plc Novel compositions
AR013261A1 (es) * 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
ATE374602T1 (de) * 2001-12-21 2007-10-15 Supernus Pharmaceuticals Inc Orale kapselformulierung mit verbesserter physikalischer stabilität
US7423004B2 (en) * 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
WO2005016312A1 (en) 2003-08-13 2005-02-24 Nobex Corporation Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
SG185631A1 (en) 2010-06-23 2012-12-28 Colgate Palmolive Co Therapeutic oral composition
EP2654672B1 (en) 2010-12-20 2017-03-08 Colgate-Palmolive Company Gelatin encapsulated oral care composition containing dental occlusion actives, hydrophobic viscosity modifier and oil carrier
EP2654671B1 (en) 2010-12-20 2019-02-20 Colgate-Palmolive Company Non-aqueous oral care composition containing dental occlusion actives
MX362101B (es) 2010-12-20 2019-01-07 Colgate Palmolive Co Composición de cuidado bucal encapsulada con gelatina que contiene agente de estructura hidrofóbico, ingrediente activo hidrofilico, y portador de aceite.
MA46713A (fr) * 2016-11-01 2019-09-11 Johnson & Johnson Consumer Inc Forme posologique pharmaceutique orale liquide comprenant un antagoniste du récepteur h2 à l'histamine et un antiacide
CN109010303B (zh) * 2017-06-09 2021-05-07 苏州科伦药物研究有限公司 一种盐酸雷尼替丁胶囊的工业制备方法
KR102108153B1 (ko) * 2017-07-05 2020-05-07 (주)동구바이오제약 생체 이용률 및 안정성이 개선된 레티노이드를 함유하는 약제학적 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
DE2360796B2 (de) * 1973-12-06 1977-06-02 Edelfettwerke Werner Schlüter, 2000 Hamburg; Glyco Iberica S.A., Gava, Barcelona (Spanien) Vti: Hegel, K.Th., Dr.; Dickel, K., Dipl.-Ing.; Pat.-Anwälte, 2000 Hamburg und 8000 München Arzneimittel mit verzoegerter abgabe des wirkstoffs im darm
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
IT1090703B (it) * 1976-12-03 1985-06-26 Scherer Ltd R P Perfezionamento nelle composizioni utili quali veicolo per farmaci
JPS5919524B2 (ja) * 1976-12-17 1984-05-07 中外製薬株式会社 安定な１α−ヒドロキシビタミンＤ類含有製剤
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
JPS55136219A (en) * 1979-04-11 1980-10-23 Sumitomo Chem Co Ltd Diazepam oily drug
EP0040489A1 (en) * 1980-05-17 1981-11-25 FISONS plc Mixtures, salts, packages and pharmaceutical compositions containing 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid or a derivative thereof and an H2 receptor antagonist antihistamine
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
CY1306A (en) * 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
DE3264782D1 (en) * 1981-10-16 1985-08-22 Sanol Arznei Schwarz Gmbh Medicinal formulation
JPS58174308A (ja) * 1982-04-06 1983-10-13 Fujimoto Seiyaku Kk レクタルカプセル坐剤
SE8302689L (sv) * 1982-05-14 1983-11-15 Richter Gedeon Vegyeszet Farmaceutiska kompositioner innehallande flera aktiva bestandsdelar
DE3237814A1 (de) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
WO1985000516A1 (en) * 1983-08-01 1985-02-14 R. P. Scherer Corporation Sustained release method and product
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
GB8426738D0 (en) * 1984-10-23 1984-11-28 Scras Pyridine derivatives
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
JPH07549B2 (ja) * 1986-07-03 1995-01-11 ゼリア新薬工業株式会社 軟カプセル充填用組成物
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
AU627775B2 (en) * 1988-09-20 1992-09-03 Glaxo Group Limited Pharmaceutical compositions

Also Published As

Publication number Publication date
IE63179B1 (en) 1995-03-22
NZ232642A (en) 1992-07-28
NL193267B (nl) 1999-01-04
AT401727B (de) 1996-11-25
SE9000625L (sv) 1990-08-24
SE9000625D0 (sv) 1990-02-22
LU87681A1 (fr) 1991-10-08
IT1240768B (it) 1993-12-17
NL9000428A (nl) 1990-09-17
CA2010692A1 (en) 1990-08-23
KR900012612A (ko) 1990-09-01
IL93490A0 (en) 1990-11-29
ATA42190A (de) 1996-04-15
GB9004016D0 (en) 1990-04-18
KR940006271B1 (ko) 1994-07-14
IT9047659A0 (it) 1990-02-22
DE4005650C2 (de) 1999-03-25
CH680567A5 (nl) 1992-09-30
ZA901348B (en) 1991-03-27
SA90100287B1 (ar) 1999-08-15
JPH03200728A (ja) 1991-09-02
DK48090A (da) 1990-08-24
ZW1790A1 (en) 1991-10-16
PH26972A (en) 1992-12-28
GB2229094B (en) 1993-01-06
HU211930A9 (en) 1996-01-29
FR2643263A1 (fr) 1990-08-24
DK170209B1 (da) 1995-06-19
GB2229094A (en) 1990-09-19
BE1003123A3 (fr) 1991-12-03
DK48090D0 (da) 1990-02-22
HK89493A (en) 1993-09-03
JP2856817B2 (ja) 1999-02-10
IL93490A (en) 1994-07-31
AU629303B2 (en) 1992-10-01
DE4005650A1 (de) 1990-09-06
NL193267C (nl) 1999-05-06
CA2010692C (en) 1995-12-12
IE900651L (en) 1990-08-23
IT9047659A1 (it) 1991-08-22
GB8904182D0 (en) 1989-04-05
FR2643263B1 (fr) 1994-09-16
US5028432A (en) 1991-07-02
AU5007390A (en) 1990-08-30
CY1734A (en) 1994-05-06

Similar Documents

Publication Publication Date Title
SE512412C2 (sv) Farmaceutisk komposition i kapselform bestående av ranitidin och en icke-vattenhaltig grundmassa
US6613353B1 (en) Pharmaceutical formulations
KR910000655B1 (ko) 신규 형태의 연질캡슐 제조방법
CA2392621A1 (en) Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
PT2279729T (pt) Preparações de libertação controlada
EP0173293B1 (en) Hot melt antihistamine formulations
US6365181B1 (en) Thixatropic gelatin carrier composition
US5175002A (en) Amantadine hydrochloride syspension with enhanced dissolution characteristics for use in soft gelatin capsules
DE1617629A1 (de) Verfahren zur Stabilisierung von Bromelin in Arzneimittelzubereitungen
US5275821A (en) Amantadine hydrochloride suspension with enhanced dissolution characteristics for use in soft gelatin capsules
EP0326103B1 (en) Pharmaceutical composition for 4-aroylimidazol-2-ones
EP0431659B1 (en) Pharmaceutical compositions of tebufelone
CA2165783C (en) Soft gelatin capsule shell compositions
CA2179041C (en) Biphasic capsule formulation
MXPA06000100A (en) Controlled release preparations
CA2310407A1 (en) Formulations comprising dissolved paroxetine
CZ20001876A3 (cs) Prostředky obsahující rozpuštěný paroxetin